A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

NCT06535737 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

DRUG: Cabozantinib

Sponsor

Chulalongkorn University

Collaborators

[object Object]